Samarth Kulkarni - Oct 13, 2024 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Executive Officer, Director
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Oct 13, 2024
Transactions value $
-$198,680
Form type
4
Date filed
10/15/2024, 06:00 PM
Previous filing
Sep 6, 2024
Next filing
Oct 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +8.33K +3.75% 231K Oct 13, 2024 Direct F1
transaction CRSP Common Shares Sale -$199K -4.29K -1.86% $46.28 227K Oct 14, 2024 Direct F2
holding CRSP Common Shares 85.6K Oct 13, 2024 The Kulkarni 2023 GRAT

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Options Exercise -8.33K -33.33% 16.7K Oct 13, 2024 Common Shares 8.33K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3 This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.